GSK says 'tailwinds' will lift its consumer healthcare business
UK drugmaker confident of staying ahead in the game even as generic drugs invade wellness segment
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
CHEAPER generic drugs, which are growing in double-digits, are invading the wellness segment of the global consumer healthcare business in a big way, giving giant drugmakers such as GlaxoSmithKline (GSK) a run for their money.
In Australia, GSK's household-name drug Panadol is facing competition from generic drugs, said Zubair Ahmed, head of consumer healthcare for Asia Pacific, the Middle East and Africa.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Autobahn Rent A Car directors declared bankrupt over S$50 million each owed to DBS
Amazon’s MGM Studios gains creative control over ‘James Bond’ franchise
UOB’s Wee Ee Cheong says S$4.9 billion Citi deal ‘paying off’ as Asean push accelerates
In taxing wealth, how far can Singapore push property owners?
